Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
- 11 January 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (5), 1066-1076
- https://doi.org/10.1080/10428194.2020.1864352
Abstract
Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B‐cell receptor (BCR) signaling pathway, which in turn prevents both B‐cell activation and BTK‐mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of BTK. Based on the results of two key phase 3 trials (ELEVATE-TN in patients with previously untreated chronic lymphocytic leukemia [CLL] and ASCEND in patients with relapsed or refractory CLL), which demonstrated superior progression-free survival while maintaining favorable tolerability, acalabrutinib was granted US Food and Drug Administration (FDA) approval in 2019 for the treatment of patients with CLL. Acalabrutinib appears to offer similar efficacy but a significantly improved tolerability profile to first-generation agents. Acalabrutinib is a good candidate to combine with other anti-cancer therapies, including B-cell lymphoma 2 inhibitors and monoclonal antibodies, a factor that may help to further improve clinical outcomes in CLL.Funding Information
- Oxford PharmaGenesis
- AstraZeneca
This publication has 50 references indexed in Scilit:
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood, 2015
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsThe New England Journal of Medicine, 2014
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyBlood, 2014
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2013
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell MalignancyInternational Reviews of Immunology, 2012
- Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in manEmerging Therapeutic Targets, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Aggressive LymphomasThe New England Journal of Medicine, 2010
- Mechanisms of B-cell lymphoma pathogenesisNature Reviews Cancer, 2005
- B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen ReceptorAnnual Review of Immunology, 2003